Literature DB >> 15665548

Decreased whole body endogenous nitric oxide production in patients with primary pulmonary hypertension.

Eric A G Demoncheaux1, Tim W Higenbottam, David G Kiely, Ju-Ming Wong, Simon Wharton, Richard Varcoe, Tom Siddons, Alan C Spivey, Keith Hall, Andy P Gize.   

Abstract

Impaired pulmonary release of nitric oxide (NO) is one of the characteristic phenotypic changes of vascular cells in pulmonary hypertension. The aim of this study was to determine nitric oxide synthase (NOS)-dependent whole body NO production in patients with primary pulmonary hypertension. NOS-dependent whole body NO production was assessed by giving an intravenous infusion of L-[(15)N](2)-arginine (50 micromol/min for 30 min) and measuring isotopic urinary enrichment of (15)N-nitrite and (15)N-nitrate. Four female patients with no signs of infection were recruited and compared with 6 age-matched control subjects. Mean 12-hour excretion of (15)N-nitrite and (15)N-nitrate in the total urine over 36 h was smaller in patients than in control subjects (57.2 +/- 27.6 vs. 229.1 +/- 65.2 nmol/mmol creatinine, p < 0.01, Mann-Whitney U test, respectively). Neither mean 12-hour excretion of (14)N-nitrite and (14)N-nitrate (51.6 +/- 10.0 vs. 72.4 +/- 10.0 micromol/mmol creatinine, p = 0.3) nor glomerular filtration rates (84.5 +/- 15.8 vs. 129.7 +/- 16.0 ml/min, p = 0.1) were different between patients and control subjects. Our results suggest that either basal NOS-dependent whole body NO production is impaired or excess NO metabolism occurs in patients with primary pulmonary hypertension. Copyright 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15665548     DOI: 10.1159/000083502

Source DB:  PubMed          Journal:  J Vasc Res        ISSN: 1018-1172            Impact factor:   1.934


  14 in total

Review 1.  Reactive oxygen and nitrogen species in pulmonary hypertension.

Authors:  Diana M Tabima; Sheila Frizzell; Mark T Gladwin
Journal:  Free Radic Biol Med       Date:  2012-03-06       Impact factor: 7.376

2.  Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis.

Authors:  A Tabarroki; D J Lindner; V Visconte; L Zhang; H J Rogers; Y Parker; H K Duong; A Lichtin; M E Kalaycio; M A Sekeres; S E Mountantonakis; G A Heresi; R V Tiu
Journal:  Leukemia       Date:  2014-01-10       Impact factor: 11.528

Review 3.  Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health.

Authors:  Carl D Koch; Mark T Gladwin; Bruce A Freeman; Jon O Lundberg; Eddie Weitzberg; Alison Morris
Journal:  Free Radic Biol Med       Date:  2016-12-16       Impact factor: 7.376

4.  Deficiency of lung antioxidants in idiopathic pulmonary arterial hypertension.

Authors:  Fares A Masri; Suzy A A Comhair; Iva Dostanic-Larson; Francisco Takao Kaneko; Raed A Dweik; Alejandro C Arroliga; Serpil C Erzurum
Journal:  Clin Transl Sci       Date:  2008-09       Impact factor: 4.689

5.  Arginine metabolic endotypes in pulmonary arterial hypertension.

Authors:  Christina C Kao; Samuel H Wedes; Jean W Hsu; Kurt M Bohren; Suzy A A Comhair; Farook Jahoor; Serpil C Erzurum
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

6.  Inhaled nebulized nitrite and nitrate therapy in a canine model of hypoxia-induced pulmonary hypertension.

Authors:  Irene Cortés-Puch; Junfeng Sun; Alan N Schechter; Steven B Solomon; Ji Won Park; Jing Feng; Cameron Gilliard; Charles Natanson; Barbora Piknova
Journal:  Nitric Oxide       Date:  2019-07-09       Impact factor: 4.427

7.  Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension.

Authors:  Suparna M Chandra; Hedi Razavi; Jongmin Kim; Rani Agrawal; Ramendra K Kundu; Vinicio de Jesus Perez; Roham T Zamanian; Thomas Quertermous; Hyung J Chun
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-01-13       Impact factor: 8.311

Review 8.  Newer approaches and novel drugs for inhalational therapy for pulmonary arterial hypertension.

Authors:  Ali Keshavarz; Hossam Kadry; Ahmed Alobaida; Fakhrul Ahsan
Journal:  Expert Opin Drug Deliv       Date:  2020-02-19       Impact factor: 6.648

9.  Pulmonary hypertension: diagnosis and management.

Authors:  Michael D McGoon; Garvan C Kane
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

10.  Nitric oxide synthases in infants and children with pulmonary hypertension and congenital heart disease.

Authors:  Thomas Hoehn; Brigitte Stiller; Allan R McPhaden; Roger M Wadsworth
Journal:  Respir Res       Date:  2009-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.